Martina C Cornel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4979848/publications.pdf

Version: 2024-02-01

220 papers	7,112 citations	71004 43 h-index	100535 70 g-index
246 all docs	246 docs citations	246 times ranked	7704 citing authors

#	Article	IF	Citations
1	Changes in opinions about human germline gene editing as a result of the Dutch DNA-dialogue project. European Journal of Human Genetics, 2023, 31, 409-416.	1.4	10
2	Pursuing Public Health Benefit Within National Genomic Initiatives: Learning From Different Policies. Frontiers in Genetics, 2022, 13, .	1.1	3
3	Dynamics of reproductive genetic technologies: Perspectives of professional stakeholders. PLoS ONE, 2022, 17, e0269719.	1.1	1
4	How will new genetic technologies, such as gene editing, change reproductive decision-making? Views of high-risk couples. European Journal of Human Genetics, 2021, 29, 39-50.	1.4	4
5	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm, 2021, 18, e1-e50.	0.3	151
6	Opportunistic genomic screening. Recommendations of the European Society of Human Genetics. European Journal of Human Genetics, 2021, 29, 365-377.	1.4	76
7	In memoriam Prof. Dr. Leo P. ten Kate. Journal of Community Genetics, 2021, 12, 1-3.	0.5	1
8	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Journal of Arrhythmia, 2021, 37, 481-534.	0.5	17
9	Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide. Journal of Community Genetics, 2021, 12, 257-265.	0.5	30
10	Uptake of fetal aneuploidy screening after the introduction of the nonâ€invasive prenatal test: A national populationâ€based register study. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1265-1272.	1.3	25
11	Expanded Neonatal Bloodspot Screening Programmes: An Evaluation Framework to Discuss New Conditions With Stakeholders. Frontiers in Pediatrics, 2021, 9, 635353.	0.9	4
12	Ensuring best practice in genomics education and evaluation: reporting item standards for education and its evaluation in genomics (RISE2 Genomics). Genetics in Medicine, 2021, 23, 1356-1365.	1.1	17
13	Moving somatic gene editing to the clinic: routes to market access and reimbursement in Europe. European Journal of Human Genetics, 2021, 29, 1477-1484.	1.4	9
14	Mainstreaming informed consent for genomic sequencing: A call for action. European Journal of Cancer, 2021, 148, 405-410.	1.3	13
15	Towards a Responsible Transition to Learning Healthcare Systems in Precision Medicine: Ethical Points to Consider. Journal of Personalized Medicine, 2021, 11, 539.	1.1	5
16	Couplesâ€™ experiences with expanded carrier screening: evaluation of a university hospital screening offer. European Journal of Human Genetics, 2021, 29, 1252-1258.	1.4	13
17	Does nonâ€invasive prenatal testing affect the livebirth prevalence of Down syndrome in the Netherlands? A populationâ€based register study. Prenatal Diagnosis, 2021, 41, 1351-1359.	1.1	14
18	Response to letter entitled: Re: Mainstreaming informed consent for genomic sequencing: A call for action. European Journal of Cancer, 2021, 155, 310-312.	1.3	0

#	Article	IF	Citations
19	Costs, burdens and the prevention of genetic disorders: what role for professional influence?. Journal of Community Genetics, 2021, 12, 503-505.	0.5	1
20	Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders. Neurology, 2021, 96, 529-540.	1.5	36
21	Expanding Neonatal Bloodspot Screening: A Multi-Stakeholder Perspective. Frontiers in Pediatrics, 2021, 9, 706394.	0.9	13
22	Roles and Responsibilities of Stakeholders in Informing Healthy Individuals on Their Genome: A Sociotechnical Analysis. SpringerBriefs in Public Health, 2021, , 77-94.	0.2	1
23	Identification of Organisational Models for the Provision of Predictive Genomic Applications. SpringerBriefs in Public Health, 2021, , 95-116.	0.2	0
24	ESHG PPPC Comments on postmortem use of genetic data for research purposes. European Journal of Human Genetics, 2020, 28, 144-146.	1.4	3
25	A new decade of community genetics: old and new challenges. Journal of Community Genetics, 2020, 11, 1-3.	0.5	2
26	The use of PROMs and shared decisionâ€making in medical encounters with patients: An opportunity to deliver valueâ€based health care to patients. Journal of Evaluation in Clinical Practice, 2020, 26, 524-540.	0.9	82
27	Contentious ethical issues in community genetics: letâ€™s talk about them. Journal of Community Genetics, 2020, 11, 5-6.	0.5	8
28	International perspectives on the implementation of reproductive carrier screening. Prenatal Diagnosis, 2020, 40, 301-310.	1.1	60
29	Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective. Frontiers in Genetics, 2020, 11, 10.	1.1	38
30	Systematic scoping review of the concept of â€˜genetic identityâ€™ and its relevance for germline modification. PLoS ONE, 2020, 15, e0228263.	1.1	8
31	Genetic Health Care Before Conception. , 2020, , 35-52.		1
32	Genomic medicine in 2025â€“2030. , 2020, , 13-24.		0
33	Genome-wide sequencing in acutely ill infants: genomic medicineâ€™s critical application?. Genetics in Medicine, 2019, 21, 498-504.	1.1	42
34	The Gen-Equip Project: evaluation and impact of genetics e-learning resources for primary care in six European languages. Genetics in Medicine, 2019, 21, 718-726.	1.1	17
35	European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death. European Journal of Human Genetics, 2019, 27, 1763-1773.	1.4	78
36	Reply to Bombard and Mighton. European Journal of Human Genetics, 2019, 27, 507-508.	1.4	0

#	Article	IF	Citations
37	Evidence-Based Genetic Education of Non-Genetic-Expert Physicians: Experiences Over Three Decades in Amsterdam. Frontiers in Genetics, 2019, 10, 712.	1.1	11
38	Value-based genomic screening: exploring genomic screening for chronic diseases using triple value principles. BMC Health Services Research, 2019, 19, 823.	0.9	4
39	How to Integrate Personalized Medicine into Prevention? Recommendations from the Personalized Prevention of Chronic Diseases (PRECeDI) Consortium. Public Health Genomics, 2019, 22, 208-214.	0.6	21
40	Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?. European Journal of Human Genetics, 2019, 27, 484-487.	1.4	11
41	Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics. European Journal of Human Genetics, 2019, 27, 169-182.	1.4	65
42	Direct-to-consumer carrier screening for cystic fibrosis via a hospital website: a 6-year evaluation. Journal of Community Genetics, 2019, 10, 249-257.	0.5	5
43	DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice. Frontiers in Pharmacology, 2019, 10, 1609.	1.6	31
44	Human germline gene editing. Recommendations of ESHG and ESHREâ€â€¡. Human Reproduction Open, 2018, 2018, hox025.	2.3	3
45	Older mothers and increased impact of prenatal screening: stable livebirth prevalence of trisomy 21 in the Netherlands for the period 2000â€“2013. European Journal of Human Genetics, 2018, 26, 157-165.	1.4	10
46	Human germline gene editing: Recommendations of ESHG and ESHRE. European Journal of Human Genetics, 2018, 26, 445-449.	1.4	30
47	Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE. European Journal of Human Genetics, 2018, 26, 450-470.	1.4	39
48	Key Implications of Data Sharing in Pediatric Genomics. JAMA Pediatrics, 2018, 172, 476.	3.3	29
49	Experiences of a Highâ€Risk Population with Prenatal Hemoglobinopathy Carrier Screening in a Primary Care Setting: a Qualitative Study. Journal of Genetic Counseling, 2018, 27, 635-646.	0.9	6
50	The challenges of the expanded availability of genomic information: an agenda-setting paper. Journal of Community Genetics, 2018, 9, 103-116.	0.5	45
51	One small edit for humans, one giant edit for humankind? Points and questions to consider for a responsible way forward for gene editing in humans. European Journal of Human Genetics, 2018, 26, 1-11.	1.4	55
52	Recent developments in genetics and medically assisted reproduction: from research to clinical applications. European Journal of Human Genetics, 2018, 26, 12-33.	1.4	76
53	Responsible innovation in human germline gene editing. Background document to the recommendations of ESHG and ESHREâ€â€¡. Human Reproduction Open, 2018, 2018, hox024.	2.3	9
54	Stakeholder Views on Active Cascade Screening for Familial Hypercholesterolemia. Healthcare (Switzerland), 2018, 6, 108.	1.0	15

#	Article	IF	Citations
55	The ethics of clinical applications of germline genome modification: a systematic review of reasons. Human Reproduction, 2018, 33, 1777-1796.	0.4	29
56	A response to the forensic genetics policy initiativeâ€™s report â€œEstablishing Best Practice for Forensic DNA Databasesâ€• Forensic Science International: Genetics, 2018, 36, e19-e21.	1.6	11
57	What do people want to know about NIPT? Content analysis of questions emailed to national NIPT information websites. Prenatal Diagnosis, 2017, 37, 412-415.	1.1	8
58	Genomic newborn screening: public health policy considerations and recommendations. BMC Medical Genomics, 2017, 10, 9.	0.7	78
59	Stakeholder perspectives on the implementation of genetic carrier screening in a changing landscape. BMC Health Services Research, 2017, 17, 146.	0.9	36
60	Implementing genetic education in primary care: the Gen-Equip programme. Journal of Community Genetics, 2017, 8, 147-150.	0.5	16
61	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2017, 92, 796-808.	2.6	40
62	Genomics for all in the 21st century?. Journal of Community Genetics, 2017, 8, 249-251.	0.5	12
63	Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis. Orphanet Journal of Rare Diseases, 2017, 12, 88.	1.2	8
64	What Do Parents of Children with Down Syndrome Think about Nonâ€•Invasive Prenatal Testing (NIPT)?. Journal of Genetic Counseling, 2017, 26, 522-531.	0.9	43
65	Ephedrine treatment for autoimmune myasthenia gravis. Neuromuscular Disorders, 2017, 27, 259-265.	0.3	26
66	Recent developments in genetics and medically-assisted reproduction: from research to clinical applicationsâ€â€¡. Human Reproduction Open, 2017, 2017, hox015.	2.3	11
67	The development of the public and professional policy committee. European Journal of Human Genetics, 2017, 25, S29-S32.	1.4	0
68	Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity. Frontiers in Pharmacology, 2017, 8, 555.	1.6	27
69	Policy Making in Newborn Screening Needs a Structured and Transparent Approach. Frontiers in Public Health, 2017, 5, 53.	1.3	16
70	Barriers and Facilitating Factors for Implementation of Genetic Services: A Public Health Perspective. Frontiers in Public Health, 2017, 5, 195.	1.3	19
71	Implementing non-invasive prenatal testing for aneuploidy in a national healthcare system: global challenges and national solutions. BMC Health Services Research, 2017, 17, 670.	0.9	55
72	Blameâ€”a novel by Tony Holtzman. Journal of Community Genetics, 2017, 8, 253-254.	0.5	1

#	Article	IF	Citations
73	Maternal Plasma DNA and RNA Sequencing for Prenatal Testing. Advances in Clinical Chemistry, 2016, 74, 63-102.	1.8	25
74	Factors for successful implementation of population-based expanded carrier screening: learning from existing initiatives: Table 1. European Journal of Public Health, 2016, 27, ckw110.	0.1	31
75	Newborn Screening Programmes in Europe, Arguments and Efforts Regarding Harmonisation: Focus on Organic Acidurias. JIMD Reports, 2016, 32, 105-115.	0.7	17
76	Mothers' Views on Longer Storage of Neonatal Dried Blood Spots for Specific Secondary Uses. Public Health Genomics, 2016, 19, 25-33.	0.6	6
77	Responsible implementation of expanded carrier screening. European Journal of Human Genetics, 2016, 24, e1-e12.	1.4	240
78	Users evaluate a detailed familial risk questionnaire as valuable and no more time consuming than a simple enquiry in a web-based diabetes risk assessment tool. Public Health, 2016, 130, 87-90.	1.4	1
79	Future of Cardiogenetics. , 2016, , 389-393.		0
80	Het voorspellen van ziekterisicoâ€™s. Bijblijven (Amsterdam, Netherlands), 2015, 31, 560-566.	0.0	0
81	Changing to NIPT as a first-tier screening test and future perspectives: opinions of health professionals. Prenatal Diagnosis, 2015, 35, 1316-1323.	1.1	28
82	Screening for Familial Hypercholesterolemia in Children: What Can We Learn From Adult Screening Programs?. Healthcare (Switzerland), 2015, 3, 1018-1030.	1.0	12
83	Effect of Comprehensive Oncogenetics Training Interventions for General Practitioners, Evaluated at Multiple Performance Levels. PLoS ONE, 2015, 10, e0122648.	1.1	29
84	Towards a European consensus for reporting incidental findings during clinical NGS testing. European Journal of Human Genetics, 2015, 23, 1601-1606.	1.4	85
85	Whole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes. European Journal of Human Genetics, 2015, 23, 1593-1600.	1.4	87
86	The Dutch national summit on preconception care: a summary of definitions, evidence and recommendations. Journal of Community Genetics, 2015, 6, 107-115.	0.5	39
87	Current and Best Practices of Genetic Testing for Maturity Onset Diabetes of the Young: Views of Professional Experts. Public Health Genomics, 2015, 18, 52-59.	0.6	16
88	Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Summary and recommendations. European Journal of Human Genetics, 2015, , .	1.4	13
89	A genetic diagnosis of maturityâ€onset diabetes of the young (<scp>MODY</scp>): experiences of patients and family members. Diabetic Medicine, 2015, 32, 1385-1392.	1.2	13
90	Effects of a simple educational intervention in well-baby clinics on womenâ€™s knowledge about and intake of folic acid supplements in the periconceptional period: a controlled trial. Public Health Nutrition, 2015, 18, 1119-1126.	1.1	14

#	Article	IF	Citations
91	Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. European Journal of Human Genetics, 2015, 23, 1438-1450.	1.4	260
92	Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials. BMJ Open, 2015, 5, e007863.	0.8	11
93	Determining the genome-wide kinship coefficient seems unhelpful in distinguishing consanguineous couples with a high versus low risk for adverse reproductive outcome. BMC Medical Genetics, 2015, 16, 50.	2.1	1
94	A decade of molecular genetic testing for MODY: a retrospective study of utilization in The Netherlands. European Journal of Human Genetics, 2015, 23, 29-33.	1.4	19
95	Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented at accountability for reasonableness. European Journal of Human Genetics, 2015, 23, 729-735.	1.4	26
96	Public attitudes towards preventive genomics and personal interest in genetic testing to prevent disease: a survey study. European Journal of Public Health, 2014, 24, 768-775.	0.1	51
97	Consanguinity and Endogamy in the Netherlands: Demographic and Medical Genetic Aspects. Human Heredity, 2014, 77, 161-166.	0.4	10
98	Sustained effects of online genetics education: a randomized controlled trial on oncogenetics. European Journal of Human Genetics, 2014, 22, 310-316.	1.4	40
99	Effectiveness of oncogenetics training on general practitionersâ€™ consultation skills: a randomized controlled trial. Genetics in Medicine, 2014, 16, 45-52.	1.1	32
100	Consanguineous marriage and reproductive risk: attitudes and understanding of ethnic groups practising consanguinity in Western society. European Journal of Human Genetics, 2014, 22, 452-457.	1.4	34
101	A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document. European Journal of Human Genetics, 2014, 22, 12-17.	1.4	49
102	Trends in genetic patent applications: the commercialization of academic intellectual property. European Journal of Human Genetics, 2014, 22, 1155-1159.	1.4	7
103	Comment on Gialluisi et al. European Journal of Human Genetics, 2014, 22, 157-157.	1.4	1
104	Informed consent for exome sequencing in diagnostics: exploring first experiences and views of professionals and patients. Clinical Genetics, 2014, 85, 417-422.	1.0	35
105	Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. Human Reproduction, 2014, 29, 1603-1609.	0.4	57
106	Factors associated with not using folic acid supplements preconceptionally. Public Health Nutrition, 2014, 17, 2344-2350.	1.1	23
107	The challenge of implementing genetic tests with clinical utility while avoiding unsound applications. Journal of Community Genetics, 2014, 5, 7-12.	0.5	25
108	Illness representations of type 2 diabetes patients are associated with perceptions of diabetes threat in relatives. Journal of Health Psychology, 2014, 19, 358-368.	1.3	12

#	Article	IF	Citations
109	Newborn screening for pompe disease? a qualitative study exploring professional views. BMC Pediatrics, 2014, 14, 203.	0.7	11
110	First steps in exploring prospective exome sequencing of consanguineous couples. European Journal of Medical Genetics, 2014, 57, 613-616.	0.7	11
111	Developing a framework for implementation of genetic services: learning from examples of testing for monogenic forms of common diseases. Journal of Community Genetics, 2014, 5, 337-347.	0.5	33
112	Neonatal diagnosis of <scp>D</scp>own syndrome in the <scp>N</scp>etherlands: suspicion and communication with parents. Journal of Intellectual Disability Research, 2014, 58, 953-961.	1.2	12
113	Reflecting on Earlier Experiences with Unsolicited Findings: Points to Consider for Nextâ€Generation Sequencing and Informed Consent in Diagnostics. Human Mutation, 2013, 34, 1322-1328.	1.1	45
114	Public attitudes towards genetic testing revisited: comparing opinions between 2002 and 2010. European Journal of Human Genetics, 2013, 21, 793-799.	1.4	103
115	Whole-genome sequencing in health care. European Journal of Human Genetics, 2013, 21, 580-584.	1.4	330
116	'A morass of considerations': exploring attitudes towards ethnicity-based haemoglobinopathy-carrier screening in primary care. Family Practice, 2013, 30, 604-610.	0.8	12
117	Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. European Journal of Human Genetics, 2013, 21, S1-S21.	1.4	120
118	Crossing the boundary between research and health care: P3G policy statement on return of results from population studies. European Journal of Human Genetics, 2013, 21, 243-244.	1.4	7
119	Developing a policy for paediatric biobanks: principles for good practice. European Journal of Human Genetics, 2013, 21, 2-7.	1.4	63
120	Call for Prudence in Whole-Genome Testing. Science, 2013, 341, 958-959.	6.0	12
121	Genetic testing and implications for personalized medicine: changes in public and healthcare professional perspectives. Personalized Medicine, 2013, 10, 217-219.	0.8	4
122	Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. European Journal of Human Genetics, 2013, 21 Suppl 1, S1-5.	1.4	66
123	A case study of haemoglobinopathy screening in the Netherlands: witnessing the past, lessons for the future. Ethnicity and Health, 2012, 17, 217-239.	1.5	12
124	Governing biological material at the intersection of care and research: the use of dried blood spots for biobanking. Croatian Medical Journal, 2012, 53, 390-397.	0.2	13
125	Prioritization of future genetics education for general practitioners: a Delphi study. Genetics in Medicine, 2012, 14, 323-329.	1.1	49
126	Attitudes of general practitioners and midwives towards ethnicity-based haemoglobinopathy-carrier screening. European Journal of Human Genetics, 2012, 20, 1112-1117.	1.4	9

#	Article	IF	Citations
127	Severely impaired health status at diagnosis of Pompe disease: A cross-sectional analysis to explore the potential utility of neonatal screening. Molecular Genetics and Metabolism, 2012, 107, 448-455.	0.5	13
128	Public support for neonatal screening for Pompe disease, a broad-phenotype condition. Orphanet Journal of Rare Diseases, 2012, 7, 15.	1.2	19
129	Patientsâ€™ intentions to inform relatives about TypeÂ2 diabetes risk: the role of worry in the process of family risk disclosure. Diabetic Medicine, 2012, 29, e461-7.	1.2	8
130	The promises of genomic screening: building a governance infrastructure. Special issue: genetics and democracy. Journal of Community Genetics, 2012, 3, 73-77.	0.5	7
131	Genetic screening and democracy: lessons from debating genetic screening criteria in the Netherlands. Journal of Community Genetics, 2012, 3, 79-89.	0.5	22
132	Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011. Journal of Inherited Metabolic Disease, 2012, 35, 635-640.	1.7	7
133	Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 â€“ From screening laboratory results to treatment, followâ€up and quality assurance. Journal of Inherited Metabolic Disease, 2012, 35, 613-625.	1.7	88
134	Family communication as strategy in diabetes prevention: An observational study in families with Dutch and Surinamese South-Asian ancestry. Patient Education and Counseling, 2012, 87, 23-29.	1.0	15
135	Counselling women about periconceptional use of folic acid: the role of the community pharmacist can be improved. International Journal of Pharmacy Practice, 2011, 7, 138-142.	0.3	5
136	Genetic testing and common disorders in a public health framework. European Journal of Human Genetics, 2011, 19, 377-381.	1.4	46
137	Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. European Journal of Human Genetics, 2011, 19, S6-S44.	1.4	75
138	Genetic educational needs and the role of genetics in primary care: a focus group study with multiple perspectives. BMC Family Practice, 2011, 12, 5.	2.9	106
139	Lay perceptions of predictive testing for diabetes based on DNA test results versus family history assessment: a focus group study. BMC Public Health, 2011, 11, 535.	1.2	16
140	Validation of self-reported folic acid use in a multiethnic population: results of the Amsterdam Born Children and their Development study. Public Health Nutrition, 2011, 14, 2022-2028.	1.1	12
141	Connective tissue: Cancer patientsâ€™ attitudes towards medical research using excised (tumour) tissue. BioSocieties, 2011, 6, 466-486.	0.8	9
142	Preconceptional genetic carrier testing and the commercial offer directly-to-consumers. Human Reproduction, 2011, 26, 972-977.	0.4	124
143	Ethical and Social Issues in Pharmacogenomics Testing. Current Pharmaceutical Design, 2010, 16, 245-252.	0.9	15
144	Translational Research in Genomics of Alzheimer's Disease: A Review of Current Practice and Future Perspectives. Journal of Alzheimer's Disease, 2010, 20, 967-980.	1.2	16

#	Article	IF	Citations
145	Autosomal recessive disease in children of consanguineous parents: inferences from the proportion of compound heterozygotes. Journal of Community Genetics, 2010, 1, 37-40.	0.5	16
146	Community genetics. Its definition 2010. Journal of Community Genetics, 2010, 1, 19-22.	0.5	26
147	Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market. Journal of Community Genetics, 2010, 1, 101-106.	0.5	97
148	Do consanguineous parents of a child affected by an autosomal recessive disease have more DNA identical-by-descent than similarly-related parents with healthy offspring? Design of a case-control study. BMC Medical Genetics, 2010, 11, 113.	2.1	15
149	Italian appeal court: a genetic predisposition to commit murder?. European Journal of Human Genetics, 2010, 18, 519-521.	1.4	39
150	Neonatal Screening for Treatable and Untreatable Disorders: Prospective Parentsâ€™ Opinions. Pediatrics, 2010, 125, e99-e106.	1.0	44
151	Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics. Public Health Genomics, 2010, 13, 106-115.	0.6	114
152	Raising awareness of carrier testing for hereditary haemoglobinopathies in high-risk ethnic groups in the Netherlands: a pilot study among the general public and primary care providers. BMC Public Health, 2009, 9, 338.	1.2	20
153	Genetic horoscopes: is it all in the genes? Points for regulatory control of direct-to-consumer genetic testing. European Journal of Human Genetics, 2009, 17, 857-859.	1.4	50
154	Preconceptional ancestry-based carrier couple screening for cystic fibrosis and haemoglobinopathies: what determines the intention to participate or not and actual participation?. European Journal of Human Genetics, 2009, 17, 999-1009.	1.4	42
155	Genetic testing in asymptomatic minors. European Journal of Human Genetics, 2009, 17, 711-719.	1.4	167
156	Direct to consumer genetic tests. European Journal of Human Genetics, 2009, 17, 1111-1111.	1.4	5
157	The expansion of newborn screening: is reproductive benefit an appropriate pursuit?. Nature Reviews Genetics, 2009, 10, 666-667.	7.7	19
158	Recreational genomics? Dreams and fears on genetic susceptibility screening. European Journal of Human Genetics, 2008, 16, 403-404.	1.4	33
159	CFTR Mutations in Turkish and North African Cystic Fibrosis Patients in Europe: Implications for Screening. Genetic Testing and Molecular Biomarkers, 2008, 12, 25-35.	1.7	18
160	Three-month follow-up of Western and non-Western participants in a study on preconceptional ancestry-based carrier couple screening for cystic fibrosis and hemoglobinopathies in the Netherlands. Genetics in Medicine, 2008, 10, 820-830.	1.1	45
161	Implementation of preconceptional carrier screening for cystic fibrosis and haemoglobinopathies: A sociotechnical analysis. Health Policy, 2007, 83, 277-286.	1.4	33
162	Developing and optimizing a decisional instrument using self-reported ancestry for carrier screening in a multi-ethnic society. Genetics in Medicine, 2006, 8, 502-509.	1.1	17

#	Article	IF	Citations
163	The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study. Pharmacoepidemiology and Drug Safety, 2006, 15, 675-682.	0.9	8
164	TypeÂ2 diabetes and inheritance: what information do diabetes organizations provide on the Internet?. Diabetic Medicine, 2006, 23, 1233-1238.	1.2	14
165	The interface between assisted reproductive technologies and genetics: technical, social, ethical and legal issues. European Journal of Human Genetics, 2006, 14, 588-645.	1.4	137
166	The need for interaction between assisted reproduction technology and genetics. European Journal of Human Genetics, 2006, 14, 509-511.	1.4	13
167	The interface between medically assisted reproduction and genetics: technical, social, ethical and legal issues*. ESHRE Monographs, 2006, 2006, 2-51.	0.6	3
168	Deficient knowledge of genetics relevant for daily practice among medical students nearing graduation. Genetics in Medicine, 2005, 7, 295-301.	1.1	58
169	Folic acidâ€"the scientific debate as a base for public health policy. Reproductive Toxicology, 2005, 20, 411-415.	1.3	47
170	Preconception Cystic Fibrosis Carrier Screening: Costs and Consequences. Genetic Testing and Molecular Biomarkers, 2005, 9, 158-166.	1.7	12
171	Current practice and future interest of GPs and prospective parents in pre-conception care in The Netherlands. Family Practice, 2004, 21, 307-309.	0.8	24
172	Attitudes of Potential Providers Towards Preconceptional Cystic Fibrosis Carrier Screening. Journal of Genetic Counseling, 2004, 13, 31-44.	0.9	30
173	Renal defects and limb deficiencies in 197 infants: Is it possible to define the â€œacrorenal syndromeâ€?. , 2004, 129A, 149-155.		9
174	Preconceptional Cystic Fibrosis Carrier Screening: Attitudes and Intentions of the Target Population. Genetic Testing and Molecular Biomarkers, 2004, 8, 80-89.	1.7	34
175	Influence of educational level on determinants of folic acid use. Paediatric and Perinatal Epidemiology, 2003, 17, 256-263.	0.8	28
176	Possibilities and barriers in the implementation of a preconceptional screening programme for cystic fibrosis carriers: a focus group study. Public Health, 2003, 117, 396-403.	1.4	30
177	How Should Preconceptional Cystic Fibrosis Carrier Screening Be Provided? Opinions of Potential Providers and the Target Population. Public Health Genomics, 2003, 6, 157-165.	0.6	16
178	Three Years after the Dutch Folic Acid Campaign: Growing Socioeconomic Differences. Preventive Medicine, 2002, 35, 65-69.	1.6	39
179	From Knowledge to Implementation. Public Health Genomics, 2002, 5, 5-7.	1.0	0
180	Is There an Association between Maternal Carbamazepine Use during Pregnancy and Eye Malformations in the Child?. Epilepsia, 2002, 43, 929-931.	2.6	21

#	Article	IF	Citations
181	Letter to the Editor: Folic acid prevents more than neural tube defects: A registry-based study in the northern Netherlands. European Journal of Epidemiology, 2002, 18, 279-280.	2.5	7
182	On the symmetry of limb deficiencies among childrenwith multiple congenital anomalies. Annales De GÃ©nÃ©tique, 2001, 44, 19-24.	0.4	8
183	Limb defects associated with major congenital anomalies: Clinical and epidemiological study from the International Clearinghouse for Birth Defects Monitoring Systems. American Journal of Medical Genetics Part A, 2000, 93, 110-116.	2.4	51
184	The Dutch 'Folic Acid Campaign'-have the goals been achieved?. Paediatric and Perinatal Epidemiology, 2000, 14, 111-117.	0.8	44
185	Accuracy of family history of cancer: clinical genetic implications. European Journal of Human Genetics, 2000, 8, 181-186.	1.4	91
186	Teratogenic Effects of Antiepileptic Drugs: Use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia, 2000, 41, 1436-1443.	2.6	186
187	Additional information from parental questionnaires and pharmacy records for registration of birth defects. EuroMAP-group. European Journal of Epidemiology, 2000, 16, 329-336.	2.5	8
188	Lower limb deficient children in the Netherlands. Prosthetics and Orthotics International, 2000, 24, 13-18.	0.5	23
189	Wealth and health in relation to birth defects mortality. Journal of Epidemiology and Community Health, 2000, 54, 644-644.	2.0	8
190	Time trends in neural tube defects prevalence in relation to preventive strategies: an international study. Journal of Epidemiology and Community Health, 1999, 53, 630-635.	2.0	68
191	Artefactual increasing frequency of omphaloceles in the Northern Netherlands: lessons for systematic analysis of apparent epidemics. International Journal of Epidemiology, 1999, 28, 258-262.	0.9	4
192	Preconceptional use of folic acid amongst women of advanced maternal age. , 1999, 19, 996-997.		1
193	Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: Pharmacist and mother as sources for drug exposure data during pregnancy. Teratology, 1999, 60, 33-36.	1.8	75
194	Periconceptional folic acid intake in the northern Netherlands. Lancet, The, 1999, 353, 1187.	6.3	38
195	Increasing awareness of and behaviour towards periconceptional folic acid consumption in The Netherlands from 1994 to 1995. European Journal of Clinical Pharmacology, 1998, 54, 329-331.	0.8	27
196	Periconceptional folic acid in The Netherlands in 1995. Socioeconomic differences. Journal of Epidemiology and Community Health, 1998, 52, 826-827.	2.0	22
197	Comparison of national policies on periconceptional use of folic acid to prevent spina bifida and anencephaly (SBA). , 1997, 55, 134-137.		60
198	A Demographic Approach to the Assessment of Down Syndrome Screening Performance. , 1997, 17, 717-724.		22

#	Article	IF	Citations
199	Population-based birth-defect and risk-factor surveillance: data from the Northern Netherlands. International Journal of Risk and Safety in Medicine, 1996, 8, 197-209.	0.3	16
200	Women's opinions on the use of folic acid. International Journal of Risk and Safety in Medicine, 1995, 7, 211-218.	0.3	0
201	Folate prophylaxis in pregnancy. Lancet, The, 1995, 346, 1227-1228.	6.3	18
202	Communicating a drug alert. European Journal of Clinical Pharmacology, 1994, 47, 125-132.	0.8	7
203	Variation in prenatal cytogenetic diagnosis: Policies in 13 european countries, 1989â€“1991. Prenatal Diagnosis, 1994, 14, 337-344.	1.1	9
204	Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment.. British Journal of Clinical Pharmacology, 1994, 38, 229-235.	1.1	31
205	Down syndrome: effects of demographic factors and prenatal diagnosis on the future livebirth prevalence. Human Genetics, 1993, 92, 163-168.	1.8	30
206	Acardius acephalus after induced ovulation: A case report. Teratology, 1993, 47, 257-262.	1.8	12
207	Registration of drug use in a birth defect monitoring system: a priority worthy of emphasis!. International Journal of Risk and Safety in Medicine, 1993, 4, 27-33.	0.3	5
208	Monitoring of risk factor/outcome combinations: a valuable supplement to birth defect monitoring. International Journal of Risk and Safety in Medicine, 1992, 3, 129-136.	0.3	2
209	Ovulation-inducing drugs: a drug utilization and risk study in the Dutch population. International Journal of Risk and Safety in Medicine, 1992, 3, 99-111.	0.3	7
210	Some epidemiological data on oral clefts in the northern Netherlands, 1981â€“1988. Journal of Cranio-Maxillo-Facial Surgery, 1992, 20, 147-152.	0.7	25
211	Ad hoc tracing of a cohort of patients exposed to acitretine (NeotigasonÂ®) on a nation-wide scale. European Journal of Clinical Pharmacology, 1992, 42, 555-557.	0.8	8
212	Acitretin (NeotigasonÂ®). Pharmaceutisch Weekblad, 1992, 14, 33-37.	0.7	4
213	Comparison of couples referred and not referred for genetic counseling in a genetic clinic after the birth of a child with a congenital anomaly: A study in a population in the northeastern Netherlands. American Journal of Medical Genetics Part A, 1992, 42, 387-392.	2.4	13
214	Prevalence of congenital heart disease in patients with phenylketonuria. Journal of Pediatrics, 1991, 119, 282-283.	0.9	12
215	Heterogeneity of neural tube defects in europe: The significance of site of defect and presence of other major anomalies in relation to geographic differences in prevalence. Teratology, 1991, 44, 547-559.	1.8	66
216	Association between holoprosencephaly and exposure to topical retinoids: results of the EUROCAT survey. Paediatric and Perinatal Epidemiology, 1991, 5, 445-447.	0.8	28

#	Article	IF	Citations
217	Consanguinity sans reproche. Human Genetics, 1991, 86, 295-296.	1.8	19
218	Association between ovulation stimulation, in vitro fertilisation, and neural tube defects?. Teratology, 1990, 42, 201-203.	1.8	11
219	Frequency of births with potentially avoidable serious chromosomal anomalies in EEC countries, 1979-1982.. Journal of Epidemiology and Community Health, 1988, 42, 266-270.	2.0	4
220	NEONATAL SCREENING FOR CYSTIC FIBROSIS. Lancet, The, 1986, 327, 802-803.	6.3	19